GSK announces marketing authorization of Exdensur in UK for added indication

GSK (GSK) announced the marketing authorization of Exdensur by the UK’s Medicines and Healthcare products Regulatory Agency. In the UK, Exdensur is now approved in two indications: as an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype who are inadequately controlled on maximum moderate-dose or high-dose inhaled corticosteroids plus another asthma controller; as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.